Peanut Allergy Clinical Trial
— GUPIOfficial title:
A Single Arm Phase II Efficacy Study of Peanut Oral Immunotherapy in Adults
NCT number | NCT03648320 |
Other study ID # | 225583 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 15, 2018 |
Est. completion date | May 19, 2022 |
Verified date | May 2024 |
Source | Guy's and St Thomas' NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine efficacy and safety of peanut oral immunotherapy in adults with peanut allergy.
Status | Completed |
Enrollment | 33 |
Est. completion date | May 19, 2022 |
Est. primary completion date | May 21, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: For peanut OIT patients: Adults aged 18-40 years with: 1. A positive skin prick test to peanut extract. 2. Elevated (>0.35) serum specific Immunoglobulin E (IgE) to Ara h 2 major peanut allergen within 2 years of date of initial screening visit. 3. Positive DBPCFC to 300mg or less of peanut protein. 4. Where appropriate, use of effective form of birth control by females for the duration of participation in the study (i.e. up to exit DBPCFC). 5. Participants with asthma may be included if well controlled: - Asthma control questionnaire (ACQ) score <1 - Maximum permitted asthma treatment: moderate dose of inhaled corticosteroid (ICS) and long-acting beta agonists (LABA) as treatment - Pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) >80% of predicted value at screening visit - For asthmatic participants with intermittent mild symptoms (induced by exercise, animals or pollens) using as required salbutamol only, treatment will be given with regular low dose inhaled corticosteroids (ICS) prior to challenges and for the duration of updosing as an additional measure. For mechanistic sub-study subjects: Adults aged 18-40 years with: 1. A positive skin prick test to peanut extract within previous 12 months 2. Elevated serum specific IgE (>0.35) to Ara h 2 major peanut allergen within 2 years of date of initial screening visit. 3. Clinical diagnosis of peanut allergy made by an experienced allergy specialist. Exclusion Criteria: For peanut OIT patients: 1. Anaphylaxis to a food other than peanut - despite attempted avoidance - within the last 2 years. 2. History of life-threatening anaphylaxis or angioedema, including previous intensive care unit (ITU) admission attributable peanut allergy. 3. Asthmatic treated with higher than moderate dose of ICS (>800 mcg equivalent of beclomethasone dipropionate (BDP) per day). 4. Any asthmatic if uncontrolled or difficult to control as evidenced by any following: ACQ>1; FEV1 <80% predicted; FEV1/ forced vital capacity (FVC) <0.7 irrespective of treatment; hospital attendance (A&E or admission) for asthma in the past 2 years; treatment of asthma with oral steroids within last 2 years. 5. Evidence of non-adherence with asthma treatment from General PRactitioner (GP) repeat prescription records. 6. Participants who react to less than 1 mg of peanut protein on DBPCFC, or who cannot tolerate at least an initial dose of 1.5 mg peanut protein on OIT initiation day. 7. Participants who react to placebo during DBPCFC. 8. Ongoing treatment with beta-blockers, biologics (such as omalizumab or mepolizumab) or systemic immunosuppressive treatment. 9. Regular ongoing use of NSAIDs for a chronic condition (NSAIDs may act as a co-factor for allergic reactions) 10. For females a positive serum or urine pregnancy test with sensitivity of less than 50 mIU/mL within 72 hours of first administration of study therapy. 11. Lactating females. 12. The use of any investigational drug within 30 days of the screening visit. 13. Past history of eosinophilic oesophagitis or chronic gastro-oesophageal reflux symptoms requiring regular treatment with anti-acids. 14. Inability to discontinue antihistamines for a minimum of 4 days prior to DBPCFC visits 15. The presence of any medical condition that the investigator deems incompatible with participation in the trial. 16. Individuals with insufficient understanding of the trial. For mechanistic sub-study subjects: 1. Ongoing treatment with biologic or systemic immunosuppressive treatment. 2. Known current pregnancy 3. Lactating females. 4. The use of any investigational drug within 30 days of the screening visit. 5. Inability to discontinue antihistamines for a minimum of 4 days prior to venesection. 6. The presence of any medical condition that the investigator deems incompatible with participation in the study. 7. Individuals with insufficient understanding of the study. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Guy's and St Thomas' NHS Foundation Trust | London |
Lead Sponsor | Collaborator |
---|---|
Guy's and St Thomas' NHS Foundation Trust | Imperial College London, King's College London, National Institute for Health Research, United Kingdom |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Desensitisation to 1.4g peanut | Tolerance of cumulative dose of 1.4g peanut protein without reaction on DBPCFC post OIT after minimum of 1 month maintenance dosing on peanut OIT | 7-8 months | |
Secondary | Desensitisation to 4.4g peanut | Tolerance of cumulative dose of 4.4 g peanut protein without reaction on DBPCFC post OIT | 7-8 months | |
Secondary | Incidence of adverse events related to treatment (safety) | Incidence of local and systemic reactions during peanut OIT updosing and maintenance | 7-8 months | |
Secondary | Reactions with ara h 8 sensitisation | Comparison of local and systemic reactions in Ara h 8 sensitised vs. non-sensitised subjects. | 7-8 months | |
Secondary | Skin prick test reactivity | Change in size of wheal diameter to peanut extract following OIT | 9 months | |
Secondary | Immunoglobulin G (IgG) levels | Change in peanut-specific IgG following OIT | 9 months | |
Secondary | Quality of life measure | Change measured using Food Allergy Quality of Life Questionnaire- Adult Form (FAQLQ-AF) and the Food Allergy Independent Measure Adult Form (FAIM-AF). These are validated questionnaires consisting of 29 (FAQLQ-AF) and 6 (FAIM-AF) questions each scored on a 7 point likert scale. The total scores are the mean score of all items with a range of 1 'no impairment' to 7 'maximal impairment'. | 7-8 months | |
Secondary | Food Neophobia score | Change measured using validated Food Neophobia Scale (FNS) questionnaire. This consists of 8 questions with answers on a 7 point likert scale ranging from 1 ("disagree strongly") to 7 ("agree strongly"). The total score is the mean score of all questions with lower score signifying increased food neophobia. | 7-8 months | |
Secondary | Food Situations score | Change using Food Situations Questionnaire, validated in children and amended to be appropriate for adults. 10 different scenarios related to food are rated from 1 (very unhappy) to 5 (very happy), giving a total possible score of 50. Higher scores are indicative of lower food neophobia. | 7-8 months | |
Secondary | Study compliance | Compliance with OIT measured using monthly diaries. | 7-8 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05667610 -
Immune-supportive Diet and Gut Permeability in Allergic Children
|
N/A | |
Recruiting |
NCT05440643 -
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
|
Phase 1 | |
Terminated |
NCT03849079 -
Validation of the HYPONUT Product
|
N/A | |
Completed |
NCT02979600 -
Clinical and Biological Efficacy of Peanut Oral Immunotherapy
|
N/A | |
Completed |
NCT01950533 -
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
|
||
Completed |
NCT01955109 -
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
|
Phase 2 | |
Recruiting |
NCT04415593 -
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
|
N/A | |
Active, not recruiting |
NCT04511494 -
Oral Immunotherapy for Young Children With Peanut Allergy - Small Children OIT
|
N/A | |
Active, not recruiting |
NCT04887441 -
Allergology: Information, Data and Knowledge Organization
|
||
Active, not recruiting |
NCT04881773 -
Oral Low Doses Tolerance INduction Study for Peanuts
|
||
Completed |
NCT03682770 -
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
|
Phase 2 | |
Terminated |
NCT03703791 -
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
|
Phase 3 | |
Completed |
NCT02916446 -
Safety Study of Viaskin Peanut to Treat Peanut Allergy
|
Phase 3 | |
Active, not recruiting |
NCT02402231 -
Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
|
Phase 2 | |
Completed |
NCT03337542 -
AR101 Real-World Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT05476497 -
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
|
Phase 1 | |
Completed |
NCT03292484 -
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
|
Phase 3 | |
Completed |
NCT03852342 -
Reactive Doses and Times During Oral Food Challenge to Peanut
|
||
Recruiting |
NCT05138757 -
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
|
Phase 1/Phase 2 | |
Completed |
NCT03352726 -
A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects
|
Phase 1 |